Dae Hun Suh
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Dae Hun Suh has a total of 166 co-authors. Here are the top co-authors by number of shared publications:
Hyuck Hoon Kwon
Oaro Dermatology Clinic, Seoul, South Korea
16 shared publicationsJi Young Yoon
Acne, Rosacea, Seborrheic Dermatitis and Hidradenitis Suppurativa Research Laboratory, Seoul National University Hospital
16 shared publicationsSeonguk Min
SnU Dermatology Clinic, Seoul, South Korea
11 shared publications- Ji Hoon Yang
Department of Dermatology Seoul National University College of Medicine Seoul Korea
9 shared publications Seon Yong Park
Department of Dermatology, Seoul National University College of Medicine, Seoul, Korea
8 shared publicationsJae Yoon Jung
Oaro Dermatology Clinic
7 shared publications
Latest Publications
- 28 July 2026
- Published by Wiley in International Journal of Dermatology
Recalcitrant Granulomatous Rosacea Successfully Managed With Oral Dapsone
- 28 July 2026
- Published by Wiley in International Journal of Dermatology
Recalcitrant Granulomatous Rosacea Successfully Managed With Oral Dapsone
- 18 February 2026
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 194 (5) , 981-983
The effect of the plant-derived prenylated flavonoid icariin on acne vulgaris and atrophic acne scars
Dear Editor, Acne vulgaris is a common skin disorder that frequently results in atrophic scarring after prolonged and excessive inflammation.1 Current treatments for acne and atrophic scars are often limited by suboptimal efficacy and tolerability.2 Given the high prevalence among adolescents and young adults, well-tolerated noninvasive therapies are needed.3 Icariin, a prenylated flavonoid, is the main bioactive compound of the Epimedium species, a plant long used in Oriental medicine.4 Preclinical studies have shown that icariin reduces inflammation, regulates lipid metabolism, inhibits Cutibacterium acnes and enhances cutaneous wound healing.4–7 These findings suggest that icariin has therapeutic potential for acne and atrophic scars, although its efficacy remains unexplored. Therefore, we conducted this clinical trial to clinically and histologically evaluate its effect (https://clinicaltrials.gov/study/NCT07076784). An 8-week, double-blinded, randomized, split-face clinical trial compared twice-daily application of 3% icariin with vehicle. Patients aged 19–39 years with inflammatory acne and atrophic scars were included. Participants applied 3% solution of icariin (TCI, Tokyo, Japan) on one randomly assigned facial side and 3% ethanol on the other, twice daily for 8 weeks. An acne expert (D.H.S.) assessed lesion and scar counts at baseline, week 4 and week 8. Skin biopsies were obtained from inflammatory lesions or medium-to-large-sized scars at baseline, with repeats at week 8 on both the icariin-treated and control sides.
- 18 February 2026
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 194 (5) , 981-983
The effect of the plant-derived prenylated flavonoid icariin on acne vulgaris and atrophic acne scars
Dear Editor, Acne vulgaris is a common skin disorder that frequently results in atrophic scarring after prolonged and excessive inflammation.1 Current treatments for acne and atrophic scars are often limited by suboptimal efficacy and tolerability.2 Given the high prevalence among adolescents and young adults, well-tolerated noninvasive therapies are needed.3 Icariin, a prenylated flavonoid, is the main bioactive compound of the Epimedium species, a plant long used in Oriental medicine.4 Preclinical studies have shown that icariin reduces inflammation, regulates lipid metabolism, inhibits Cutibacterium acnes and enhances cutaneous wound healing.4–7 These findings suggest that icariin has therapeutic potential for acne and atrophic scars, although its efficacy remains unexplored. Therefore, we conducted this clinical trial to clinically and histologically evaluate its effect (https://clinicaltrials.gov/study/NCT07076784). An 8-week, double-blinded, randomized, split-face clinical trial compared twice-daily application of 3% icariin with vehicle. Patients aged 19–39 years with inflammatory acne and atrophic scars were included. Participants applied 3% solution of icariin (TCI, Tokyo, Japan) on one randomly assigned facial side and 3% ethanol on the other, twice daily for 8 weeks. An acne expert (D.H.S.) assessed lesion and scar counts at baseline, week 4 and week 8. Skin biopsies were obtained from inflammatory lesions or medium-to-large-sized scars at baseline, with repeats at week 8 on both the icariin-treated and control sides.
- Open Access
- 18 December 2025
- Published by Springer Nature in Dermatology and Therapy
- Vol. 16 (9) , 4341-4354
Comparison of Efficacy of Intradermal Stromal Vascular Fraction Injection Versus Saline Injection in the Treatment of Atrophic Acne Scar: A 10-Week, Prospective, Randomized, Split-Face, Single-Blind Controlled Trial
Management of atrophic acne scars remains challenging, and conventional treatments often yield suboptimal or inconsistent outcomes. Stromal vascular fraction (SVF), a cell-rich fraction derived from adipose tissue, has recently gained attention as a promising regenerative therapy. Several previous studies have reported benefits of SVF when combined with other treatment modalities; however, its stand-alone efficacy for atrophic acne scars has not been clearly investigated. In addition, molecular evidence supporting the regenerative effects of SVF in acne scar treatment remains limited. This randomized, evaluator-blinded, split-face clinical trial was conducted in 14 patients with bilateral facial atrophic acne scars. One side was treated with intradermal SVF injection, while the contralateral side received normal saline (NS). Clinical outcomes were assessed using scar counts, Évaluation Clinique des Cicatrices d'Acne (ECCA) scores, Scar Global Assessment (SGA) scores, and standardized photography at baseline, 5 weeks, and 10 weeks. Skin biopsies were analyzed via immunohistochemistry for markers of epidermal regeneration (cytokeratin 14, cytokeratin 15, p63, integrin β1) and dermal remodeling (collagen I, elastin, vimentin). At 10 weeks after initial treatment, the SVF-treated side showed a significantly greater reduction in total scar count compared to the NS-treated side (56.4% vs. 13.2%, p < 0.001). Scar subtype analysis revealed that all scar types (ice pick, boxcar, and rolling) responded more favorably to SVF treatment, with large effect sizes (Cohen's d > 0.99). ECCA and SGA scores were also significantly decreased on the SVF-treated side. Immunohistochemical analysis revealed marked upregulation of epidermal progenitor markers and increased deposition of collagen I, elastin, and vimentin in the SVF-treated tissue. We clinically demonstrated that SVF injection improves atrophic acne scars and simultaneously revealed its regenerative mechanisms involving epidermal and dermal remodeling. This supports the use of SVF as an evidence-based treatment modality for atrophic acne scars. ClinicalTrials.gov Identifier, NCT07094958.
- 18 December 2025
- Published by Springer Nature in Dermatology and Therapy
- Vol. 16 (9) , 4341-4354
Open AccessComparison of Efficacy of Intradermal Stromal Vascular Fraction Injection Versus Saline Injection in the Treatment of Atrophic Acne Scar: A 10-Week, Prospective, Randomized, Split-Face, Single-Blind Controlled Trial
Management of atrophic acne scars remains challenging, and conventional treatments often yield suboptimal or inconsistent outcomes. Stromal vascular fraction (SVF), a cell-rich fraction derived from adipose tissue, has recently gained attention as a promising regenerative therapy. Several previous studies have reported benefits of SVF when combined with other treatment modalities; however, its stand-alone efficacy for atrophic acne scars has not been clearly investigated. In addition, molecular evidence supporting the regenerative effects of SVF in acne scar treatment remains limited. This randomized, evaluator-blinded, split-face clinical trial was conducted in 14 patients with bilateral facial atrophic acne scars. One side was treated with intradermal SVF injection, while the contralateral side received normal saline (NS). Clinical outcomes were assessed using scar counts, Évaluation Clinique des Cicatrices d'Acne (ECCA) scores, Scar Global Assessment (SGA) scores, and standardized photography at baseline, 5 weeks, and 10 weeks. Skin biopsies were analyzed via immunohistochemistry for markers of epidermal regeneration (cytokeratin 14, cytokeratin 15, p63, integrin β1) and dermal remodeling (collagen I, elastin, vimentin). At 10 weeks after initial treatment, the SVF-treated side showed a significantly greater reduction in total scar count compared to the NS-treated side (56.4% vs. 13.2%, p < 0.001). Scar subtype analysis revealed that all scar types (ice pick, boxcar, and rolling) responded more favorably to SVF treatment, with large effect sizes (Cohen's d > 0.99). ECCA and SGA scores were also significantly decreased on the SVF-treated side. Immunohistochemical analysis revealed marked upregulation of epidermal progenitor markers and increased deposition of collagen I, elastin, and vimentin in the SVF-treated tissue. We clinically demonstrated that SVF injection improves atrophic acne scars and simultaneously revealed its regenerative mechanisms involving epidermal and dermal remodeling. This supports the use of SVF as an evidence-based treatment modality for atrophic acne scars. ClinicalTrials.gov Identifier, NCT07094958.
- 1 July 2024
- Published by Edizioni Minerva Medica in Italian Journal of Dermatology and Venereology
- Vol. 159 (4) , 444-452
Investigation of the effect of adapalene 0.3%/benzoyl peroxide 2.5% gel in Korean patients with acne: a randomized, double-blind clinical trial, with a histopathological and immunohistochemical study
Article: Investigation of the effect of adapalene 0.3%/benzoyl peroxide 2.5% gel in Korean patients with acne: a randomized, double-blind clinical trial, with a histopathological and immunohistochemical study - Italian Journal of Dermatology and Venereology 2024 August;159(4):444-52 - Minerva Medica - Journals
- 1 July 2024
- Published by Edizioni Minerva Medica in Italian Journal of Dermatology and Venereology
- Vol. 159 (4) , 444-452
Investigation of the effect of adapalene 0.3%/benzoyl peroxide 2.5% gel in Korean patients with acne: a randomized, double-blind clinical trial, with a histopathological and immunohistochemical study
Article: Investigation of the effect of adapalene 0.3%/benzoyl peroxide 2.5% gel in Korean patients with acne: a randomized, double-blind clinical trial, with a histopathological and immunohistochemical study - Italian Journal of Dermatology and Venereology 2024 August;159(4):444-52 - Minerva Medica - Journals
- Open Access
- 21 June 2024
- Published by Springer Nature in Archives of Dermatological Research
- Vol. 316 (7) , 1-10
Potential of cannabidiol as acne and acne scar treatment: novel insights into molecular pathways of pathophysiological factors
Cannabidiol (CBD), which is derived from hemp, is gaining recognition because of its anti-inflammatory and lipid-modulating properties that could be utilized to treat acne. We conducted experiments to quantitatively assess the effects of CBD on acne-related cellular pathways. SEB-1 sebocytes and HaCaT keratinocytes were exposed to various CBD concentrations. CBD exhibited a concentration-dependent impact on cell viability and notably reduced SEB-1 viability; furthermore, it induced apoptosis and a significant increase in the apoptotic area at higher concentrations. Additionally, CBD remarkably reduced pro-inflammatory cytokines, including CXCL8, IL-1α, and IL-1β. Additionally, it inhibited lipid synthesis by modulating the AMPK-SREBP-1 pathway and effectively reduced hyperkeratinization-related protein keratin 16. Simultaneously, CBD stimulated the synthesis of elastin, collagen 1, and collagen 3. These findings emphasize the potential of CBD for the management of acne because of its anti-inflammatory, apoptotic, and lipid-inhibitory effects. Notably, the modulation of the Akt/AMPK-SREBP-1 pathway revealed a novel and promising mechanism that could address the pathogenesis of acne.
- 21 June 2024
- Published by Springer Nature in Archives of Dermatological Research
- Vol. 316 (7) , 1-10
Open AccessPotential of cannabidiol as acne and acne scar treatment: novel insights into molecular pathways of pathophysiological factors
Cannabidiol (CBD), which is derived from hemp, is gaining recognition because of its anti-inflammatory and lipid-modulating properties that could be utilized to treat acne. We conducted experiments to quantitatively assess the effects of CBD on acne-related cellular pathways. SEB-1 sebocytes and HaCaT keratinocytes were exposed to various CBD concentrations. CBD exhibited a concentration-dependent impact on cell viability and notably reduced SEB-1 viability; furthermore, it induced apoptosis and a significant increase in the apoptotic area at higher concentrations. Additionally, CBD remarkably reduced pro-inflammatory cytokines, including CXCL8, IL-1α, and IL-1β. Additionally, it inhibited lipid synthesis by modulating the AMPK-SREBP-1 pathway and effectively reduced hyperkeratinization-related protein keratin 16. Simultaneously, CBD stimulated the synthesis of elastin, collagen 1, and collagen 3. These findings emphasize the potential of CBD for the management of acne because of its anti-inflammatory, apoptotic, and lipid-inhibitory effects. Notably, the modulation of the Akt/AMPK-SREBP-1 pathway revealed a novel and promising mechanism that could address the pathogenesis of acne.
- 28 February 2024
- Published by Wiley in Australasian Journal of Dermatology
- Vol. 65 (4) , 311-318
Alterations in epidermal stem cells within the pilosebaceous unit in atrophic acne scars
Background: Atrophic acne scarring is a common sequela of inflammatory acne, causing significant problems for affected patients. Although prolonged inflammation and subsequent aberrant tissue regeneration are considered the underlying pathogenesis, the role of epidermal stem cells, which are crucial to the regeneration of pilosebaceous units, remains unknown.Objectives: To examine the changes occurring in epidermal stem cells in atrophic acne scars.Methods: Changes in collagen, elastic fibre and human leukocyte antigen (HLA)‐DR expression were analysed in normal skin and inflammatory acne lesions at days 1, 3 and 7 after development. The expression of epidermal stem cell markers and proliferation markers was compared between normal skin and mature atrophic acne scar tissue.Results: In acne lesions, inflammation had invaded into pilosebaceous units over time. Their normal structure had been destructed and replaced with a reduced amount of collagen and elastic fibre. Expression of stem cell markers including CD34, p63, leucine‐rich repeat‐containing G protein‐coupled receptor (LGR)6 and LGR5, which are expressed in the interfollicular epidermis, isthmus and bulge of hair follicles, significantly decreased in atrophic acne scar tissue compared to normal skin. Epidermal proliferation was significantly reduced in scar tissue.Conclusions: These findings suggest that as inflammatory acne lesions progress, inflammation gradually infiltrates the pilosebaceous unit and affects the resident stem cells. This disruption impedes the normal regeneration of the interfollicular epidermis and adnexal structures, resulting in atrophic acne scars.
- 28 February 2024
- Published by Wiley in Australasian Journal of Dermatology
- Vol. 65 (4) , 311-318
Alterations in epidermal stem cells within the pilosebaceous unit in atrophic acne scars
Background: Atrophic acne scarring is a common sequela of inflammatory acne, causing significant problems for affected patients. Although prolonged inflammation and subsequent aberrant tissue regeneration are considered the underlying pathogenesis, the role of epidermal stem cells, which are crucial to the regeneration of pilosebaceous units, remains unknown.Objectives: To examine the changes occurring in epidermal stem cells in atrophic acne scars.Methods: Changes in collagen, elastic fibre and human leukocyte antigen (HLA)‐DR expression were analysed in normal skin and inflammatory acne lesions at days 1, 3 and 7 after development. The expression of epidermal stem cell markers and proliferation markers was compared between normal skin and mature atrophic acne scar tissue.Results: In acne lesions, inflammation had invaded into pilosebaceous units over time. Their normal structure had been destructed and replaced with a reduced amount of collagen and elastic fibre. Expression of stem cell markers including CD34, p63, leucine‐rich repeat‐containing G protein‐coupled receptor (LGR)6 and LGR5, which are expressed in the interfollicular epidermis, isthmus and bulge of hair follicles, significantly decreased in atrophic acne scar tissue compared to normal skin. Epidermal proliferation was significantly reduced in scar tissue.Conclusions: These findings suggest that as inflammatory acne lesions progress, inflammation gradually infiltrates the pilosebaceous unit and affects the resident stem cells. This disruption impedes the normal regeneration of the interfollicular epidermis and adnexal structures, resulting in atrophic acne scars.
- Open Access
- 1 January 2024
- Published by XMLink in Annals of Dermatology
- Vol. 36 (2) , 81-90
Facial Dermatoses Associated With Mask-Wearing in the COVID-19 Era: A Nationwide, Cross-Sectional, Multicenter, Questionnaire-based Study
Choi ME, et al. Ann Dermatol. 2024 Apr;36(2):81-90. https://doi.org/10.5021/ad.23.061
- 1 January 2024
- Published by XMLink in Annals of Dermatology
- Vol. 36 (2) , 81-90
Open AccessFacial Dermatoses Associated With Mask-Wearing in the COVID-19 Era: A Nationwide, Cross-Sectional, Multicenter, Questionnaire-based Study
Choi ME, et al. Ann Dermatol. 2024 Apr;36(2):81-90. https://doi.org/10.5021/ad.23.061
- Open Access
- 1 January 2024
- Published by XMLink in Annals of Dermatology
- Vol. 36 (1) , 35-43
Consensus Report on Truncal Acne: The Korean Acne and Rosacea Society Experts Panel
Ko JY, et al. Ann Dermatol. 2024 Feb;36(1):35-43. https://doi.org/10.5021/ad.23.057
- 1 January 2024
- Published by XMLink in Annals of Dermatology
- Vol. 36 (1) , 35-43
Open AccessConsensus Report on Truncal Acne: The Korean Acne and Rosacea Society Experts Panel
Ko JY, et al. Ann Dermatol. 2024 Feb;36(1):35-43. https://doi.org/10.5021/ad.23.057
- Open Access
- 6 September 2023
- Published by S. Karger AG in Case Reports in Dermatology
- Vol. 15 (1) , 152-155
Primary Cutaneous Marginal Zone Lymphoma following Repeated Inflammation Caused by Hair Dyeing
Primary cutaneous marginal zone lymphoma (PCMZL) is a rare form of B-cell lymphoma that primarily affects the skin. Chronic antigen stimulation has been implicated in its development, with cases associated with various triggers. We present a case of PCMZL following chronic inflammation caused by long-term hair dyeing. A 75-year-old woman with a history of repeated inflammation and itching after hair dyeing for 30 years presented with persistent red-to-violaceous patches and plaques on her scalp. Despite receiving topical corticosteroid treatment for 10 years, the lesions remained. Pathological examinations confirmed the diagnosis of PCMZL. The patient achieved complete remission after radiotherapy. This case underscores the potential link between chronic inflammation and the development of PCMZL.
- 6 September 2023
- Published by S. Karger AG in Case Reports in Dermatology
- Vol. 15 (1) , 152-155
Open AccessPrimary Cutaneous Marginal Zone Lymphoma following Repeated Inflammation Caused by Hair Dyeing
Primary cutaneous marginal zone lymphoma (PCMZL) is a rare form of B-cell lymphoma that primarily affects the skin. Chronic antigen stimulation has been implicated in its development, with cases associated with various triggers. We present a case of PCMZL following chronic inflammation caused by long-term hair dyeing. A 75-year-old woman with a history of repeated inflammation and itching after hair dyeing for 30 years presented with persistent red-to-violaceous patches and plaques on her scalp. Despite receiving topical corticosteroid treatment for 10 years, the lesions remained. Pathological examinations confirmed the diagnosis of PCMZL. The patient achieved complete remission after radiotherapy. This case underscores the potential link between chronic inflammation and the development of PCMZL.